Smoltek's Nomination Committee proposes the election of two new Board members

This press release is an English version of the previously published Swedish version, which has interpretive precedence.

Smoltek Nanotech Holding AB (“Smoltek”) announces that the company's Nomination Committee proposes Edvard Kälvesten and Per Zellman to be elected as new Board members at the Annual General Meeting on May 12, 2022. The proposed members are deemed to provide the Board with valuable expertise in company development as well as industrialization and commercialization of disruptive technology.

Smoltek continues to develop from a research-driven company to an innovative industrial company. The company is now entering a partly new phase where the development of disruptive technology in a complex and global value chain continues to be at the centre, while collaborations with partners and customers are becoming increasingly important. To ensure that Smoltek's Board has the right competence profile during this phase, the Nomination Committee proposes that the following persons be elected as new Board members at the forthcoming Annual General Meeting:

Edvard Kälvesten, CEO and founder of Silex Microsystems AB, the world's largest pure-play foundry within microsensors. With a doctorate in microsensors and a strong technical as well as entrepreneurial focus, Edvard has successfully built Silex from the ground up to a company with an annual revenue of over one billion SEK. Edvard has deep knowledge within Smoltek's business area aimed at the semiconductor industry, and he will contribute with the company-building experience that Smoltek needs. Edvard currently has three active board assignments in Myvox AB, SensiTib AB and Silex Microsystems International AB.

Per Zellman, CEO and owner of Exezell AB, his own consulting company in professional services. Per has a M.Sc. in electrical engineering, and extensive international experience from various roles as CEO and commercial manager at, among others, Emotrongruppen, CG Drives & Automation AB, Norstel and Epiluvac. Per will contribute with expertise in both business development and commercial development, i.e. how a company should be positioned in a strategic and commercial perspective. Per has previous board experience from, among others, Norstel AB, Ascatron AB and Acosense AB.

“The members of the Nomination Committee are pleased to have identified these two candidates, as we are convinced that they have the right profile to make a positive contribution to Smoltek's future development. Both Edvard and Per will contribute with a solid business acumen and experience from leading fast-growing technology companies, and above all how to best commercialize disruptive technology in a global arena,” says Lena Olving, chair of the Nomination Committee.

“This proposition to strengthen Smoltek's Board is fully in line with our ambition to ensure that the company has an optimal structure with the necessary capacity and competence to turn our unique and pioneering technology platform into commercial products,” says Peter Augustsson, Smoltek's Chairman of the Board.

The proposed board members will, if elected, replace the current members Peter Enoksson and Bo Hedfors who have declined re-election.

More information about Smoltek's Annual General Meeting can be found in the notice of the Annual General Meeting, which was published on April 12, 2022.

For further information: 
Håkan Persson, CEO of Smoltek Nanotech Holding AB,
E-mail: hakan.persson@smoltek.com  
Phone: +46 760 52 00 53
Website: www.smoltek.com/investors   

Smoltek develops process technology and concepts for applications based on carbon nanotechnology to solve advanced materials engineering problems in several industrial sectors. The company protects its unique technology through an extensive and expanding patent portfolio consisting of around 100 applied for patents, of which today 72 have been granted. Smoltek's share is listed on the Spotlight Stock Market in Stockholm, Sweden under the ticker SMOL. Smoltek is a development company, and forward-looking statements regarding time to market, production volume and price levels should be interpreted as forecasts and not commitments.